SG11202011969WA - Methods for characterizing protein complexes - Google Patents
Methods for characterizing protein complexesInfo
- Publication number
- SG11202011969WA SG11202011969WA SG11202011969WA SG11202011969WA SG11202011969WA SG 11202011969W A SG11202011969W A SG 11202011969WA SG 11202011969W A SG11202011969W A SG 11202011969WA SG 11202011969W A SG11202011969W A SG 11202011969WA SG 11202011969W A SG11202011969W A SG 11202011969WA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- protein complexes
- characterizing protein
- characterizing
- complexes
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/47—Scattering, i.e. diffuse reflection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/47—Scattering, i.e. diffuse reflection
- G01N21/49—Scattering, i.e. diffuse reflection within a body or fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/0005—Field flow fractionation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862724700P | 2018-08-30 | 2018-08-30 | |
| PCT/US2019/048526 WO2020047067A1 (en) | 2018-08-30 | 2019-08-28 | Methods for characterizing protein complexes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202011969WA true SG11202011969WA (en) | 2020-12-30 |
Family
ID=68063024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202011969WA SG11202011969WA (en) | 2018-08-30 | 2019-08-28 | Methods for characterizing protein complexes |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11754569B2 (es) |
| EP (1) | EP3775926A1 (es) |
| JP (1) | JP2021535361A (es) |
| KR (1) | KR20210053816A (es) |
| CN (1) | CN112601963A (es) |
| AU (1) | AU2019333047A1 (es) |
| BR (1) | BR112020026348A2 (es) |
| CA (1) | CA3100038A1 (es) |
| EA (1) | EA202190032A1 (es) |
| IL (1) | IL280884A (es) |
| MX (1) | MX2021002281A (es) |
| SG (1) | SG11202011969WA (es) |
| TW (1) | TW202024639A (es) |
| WO (1) | WO2020047067A1 (es) |
| ZA (1) | ZA202007067B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020327000A1 (en) | 2019-08-08 | 2022-03-31 | Regeneron Pharmaceuticals, Inc. | Novel antigen binding molecule formats |
| WO2023004282A2 (en) | 2021-07-19 | 2023-01-26 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| TW202334223A (zh) | 2021-11-11 | 2023-09-01 | 美商再生元醫藥公司 | Ｃｄ２０－ｐｄ１結合分子及其使用方法 |
| CN114874349B (zh) * | 2022-06-15 | 2023-03-10 | 河北大学 | 一种基于场流分离技术分离纯化灵芝多糖的方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6927004B2 (en) | 2002-03-08 | 2005-08-09 | Asml Netherlands B.V. | Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| AU2008282152B2 (en) | 2007-07-31 | 2013-12-19 | Regeneron Pharmaceuticals, Inc. | Human antibodies to human CD20 and method of using thereof |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| KR102010827B1 (ko) | 2009-06-26 | 2019-08-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| WO2011121560A2 (en) | 2010-03-31 | 2011-10-06 | Universite De Geneve | Stabilized antibody preparations and uses thereof |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| JOP20190250A1 (ar) | 2010-07-14 | 2017-06-16 | Regeneron Pharma | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب |
| AR083044A1 (es) | 2010-09-27 | 2013-01-30 | Regeneron Pharma | Anticuerpos anti-cd48 y usos de los mismos |
| EA034617B1 (ru) | 2010-10-06 | 2020-02-27 | Ридженерон Фармасьютикалз, Инк. | Дозированная форма жидкой фармацевтической композиции, содержащей антитела к рецептору интерлейкина-4 (il-4r) |
| JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| JO3412B1 (ar) | 2011-06-17 | 2019-10-20 | Regeneron Pharma | أجسام مضادة ل angptl3 واستخداماتها |
| PT2780368T (pt) | 2011-11-14 | 2018-03-22 | Regeneron Pharma | Composições e métodos para aumentar a massa muscular e a força muscular antagonizando especificamente gdf8 e/ou activina a |
| BR112014017882A2 (pt) | 2012-01-23 | 2017-06-27 | Regeneron Pharma | formulações estabilizadas contendo anticorpos anti-ang-2 |
| US10481164B2 (en) * | 2012-03-26 | 2019-11-19 | Amgen Inc. | Method for using light scattering in real time to directly monitor and control impurity removal in purification processes |
| ES2729715T3 (es) | 2012-04-17 | 2019-11-05 | Aeneas Gmbh & Co Kg | Procedimiento para el diagnóstico presintomático de enfermedad celíaca y sensibilidad al gluten |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| TW201843172A (zh) | 2012-06-25 | 2018-12-16 | 美商再生元醫藥公司 | 抗－ｅｇｆｒ抗體及其用途 |
| EP2882778B1 (en) | 2012-08-13 | 2018-04-11 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| TWI659968B (zh) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 |
| JP6404314B2 (ja) | 2013-03-15 | 2018-10-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｉｌ−３３拮抗薬とその使用法 |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| RS59077B1 (sr) | 2014-03-11 | 2019-09-30 | Regeneron Pharma | Anti-egfrviii antitela i njihova primena |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| US9795121B2 (en) | 2014-05-05 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Humanized C3 animals |
| JO3701B1 (ar) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي |
| JP2017533695A (ja) | 2014-09-16 | 2017-11-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗グルカゴン抗体およびその使用 |
| TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
| BR112018014668A2 (pt) | 2016-01-27 | 2018-12-11 | Csl Behring Recombinant Facility Ag | multímeros de fc de igg recombinante |
| WO2019118556A1 (en) * | 2017-12-13 | 2019-06-20 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody combinations and uses thereof |
-
2019
- 2019-08-28 US US16/553,312 patent/US11754569B2/en active Active
- 2019-08-28 CA CA3100038A patent/CA3100038A1/en active Pending
- 2019-08-28 SG SG11202011969WA patent/SG11202011969WA/en unknown
- 2019-08-28 EP EP19773980.8A patent/EP3775926A1/en active Pending
- 2019-08-28 KR KR1020207037969A patent/KR20210053816A/ko not_active Application Discontinuation
- 2019-08-28 EA EA202190032A patent/EA202190032A1/ru unknown
- 2019-08-28 BR BR112020026348-6A patent/BR112020026348A2/pt unknown
- 2019-08-28 MX MX2021002281A patent/MX2021002281A/es unknown
- 2019-08-28 TW TW108130758A patent/TW202024639A/zh unknown
- 2019-08-28 AU AU2019333047A patent/AU2019333047A1/en active Pending
- 2019-08-28 WO PCT/US2019/048526 patent/WO2020047067A1/en unknown
- 2019-08-28 JP JP2021504752A patent/JP2021535361A/ja active Pending
- 2019-08-28 CN CN201980055175.3A patent/CN112601963A/zh active Pending
-
2020
- 2020-11-12 ZA ZA2020/07067A patent/ZA202007067B/en unknown
-
2021
- 2021-02-15 IL IL280884A patent/IL280884A/en unknown
-
2023
- 2023-07-06 US US18/218,957 patent/US20240019443A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11754569B2 (en) | 2023-09-12 |
| CA3100038A1 (en) | 2020-03-05 |
| US20240019443A1 (en) | 2024-01-18 |
| CN112601963A (zh) | 2021-04-02 |
| BR112020026348A2 (pt) | 2021-03-30 |
| EA202190032A1 (ru) | 2021-03-12 |
| KR20210053816A (ko) | 2021-05-12 |
| WO2020047067A1 (en) | 2020-03-05 |
| TW202024639A (zh) | 2020-07-01 |
| IL280884A (en) | 2021-04-29 |
| EP3775926A1 (en) | 2021-02-17 |
| JP2021535361A (ja) | 2021-12-16 |
| US20200072844A1 (en) | 2020-03-05 |
| AU2019333047A1 (en) | 2020-12-03 |
| ZA202007067B (en) | 2024-04-24 |
| MX2021002281A (es) | 2021-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281804A (en) | Protein purification methods | |
| IL288613A (en) | Multispecific proteins | |
| IL280884A (en) | Methods for characterizing protein complexes | |
| DK3737402T3 (en) | Modificeret protein | |
| IL263342A (en) | A method for stabilizing proteins | |
| EP3463414C0 (en) | PROTEIN INTERFACES | |
| IL279355A (en) | Antigen binding protein against STEAP1 | |
| IL281088A (en) | FLT3L - based chimeric proteins | |
| GB201803724D0 (en) | Methods | |
| SG11202109901TA (en) | Protein binders for irhom2 | |
| IL292145A (en) | Methods for protein characterization in host cells | |
| IL284317A (en) | FAB pseudoproteins are multispecific binding proteins | |
| IL258340A (en) | Quantifying met protein for cancer treatment | |
| GB201802486D0 (en) | Methods | |
| GB201708330D0 (en) | Fusion protein for enhancing intestinal regeneration | |
| GB201815670D0 (en) | Protein editing | |
| ZA201901862B (en) | Modified factor h binding protein | |
| SG11202007342QA (en) | Methods | |
| GB201805466D0 (en) | Methods | |
| GB2558968B (en) | G Proteins | |
| EP3784679C0 (en) | PHOSPHINIMINE AMIDO-ETHER COMPLEXES | |
| GB201814451D0 (en) | Methods | |
| GB201703416D0 (en) | Method for protein expression | |
| GB201703049D0 (en) | Single-strand binding protein | |
| GB201614627D0 (en) | Antigen binding proteins |